Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccination in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who receive the scheduled cytotoxic chemotherapy every 3 weeks because of solid cancer.~   Specific definition of each term is like following:~  * The solid cancer includes various kinds of cancer except hematologic and lymphoid malignancies.~  * Cytotoxic chemotherapy includes adjuvant, neoadjuvant or palliative purpose of chemotherapy with the planned duration at least over 3 cycles every 3 weeks.~  * Targeted therapy drugs like as monoclonal antibody, tyrosine kinase inhibitor or oral chemotherapy drugs like as Xeloda are excluded.~2. Patients who did not receive the influenza vaccination yet in the current year.~3. Older than 19 years~4. Eastern Cooperative Oncology Group (ECOG) performance status is 0, 1, or 2~5. Cell blood count meets following criteria:~   * Neutrophile count ≥ 1.5 x 10\^9/L~  * Platelet count ≥ 100 x 10\^9/L~  * Hemoglobin ≥ 8 g/dL~6. Patients who can understand and agreed with the informed consents.~Exclusion Criteria:~1. Patients who have any contraindication for influenza vaccination.~2. Patients who are supposed to receive the last chemotherapy at the enrollment~3. Patients who receive simultaneous radiation therapy with cytotoxic chemotherapy~4. Patients who receive any immunosuppressant (excluding steroid for anti-emetic effect)~5. Patients with HIV and low CD 4+ T cell count (\< 500/uL)~6. Patients with autoimmune disease who are anticipated to have a problem with immunogenicity for vaccine~7. Patients who have transplanted organ and receive immunosuppressants~8. Patients who are supposed to get prophylactic G-CSF after chemotherapy~9. Patients who are suspected to have active infectious disease.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Day 1 vaccination (Type: EXPERIMENTAL): Different timing of influenza vaccination: Day 1~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts.
- Day 11 vaccination (Type: ACTIVE_COMPARATOR): Different timing of influenza vaccination: Day 11~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts

Based on this trial design, predict the completion outcome and termination type (if applicable).